Research, Report & Profiling Services by IPOdesktop.com Integramed America Inc. (INMD) Stock symbol: INMD…..…….………….………..……...….….……………..Ave vol (3m) 12,140 Stock price 11/17/08: $5.74……………………….……………Common shares 9/30/08: 8.7mm 52 week price range: Hi/Low $4.30 to $15.34…...….……Equity market capitalization: $50mm

Recent News…..Stock Price…..Chart…..SEC Filings

BUSINESS

Dominant in two growing US healthcare segments

Fertility – Leading/Only provider of complete fertility services – Performs approx. 25% of all IVF procedures in US.

Vein Care – Entered segment via Aug. 2007 acquisition of Vein Clinics of America. Leading US network of vein care clinics; non surgical treatment of varicose veins. No viable competitors on horizon

Supports Centers with strong business infrastructure:

FINANCIALS

For the three months ended September 30, 2008 Q3 EPS Rose 18% to $0.13, Revenues Grew 30% to $52.3 Million

. Revenue composition: 70% Fertility; 10% Consumer Services (offers products directly to fertility patients); 20% Vein Care

. Net income of $1.15mm

. $22.4mm of cash

. $52mm of shareholder’s equity

MARKETS

Fertility

US Fertility Sector: 3 billion spent annually on diagnostic, medical, surgical and assisted reproductive technology, growth 3% annually

Fertility sector remains strong and INMD is the market leader, with solid infrastructure and growth potential.

Vein Care

US Vein Care Sector: Sector estimated at approx. $2 billion, a fragmented market, growing 12% annually

Vein Care market is growing and Vein Clinics of America is the market leader.

MARKET POSITION

INMD Fertility Network in a $3 Billion marketplace: . 31 fertility centers with 101 locations and 171 physicians and PhD scientists . 4 of the top 5 fertility practices in the U.S., (by volume of procedures) . 25% of all IVF volume in the U.S. . No competitors providing similar practice support services and consumer products

Vein Care = ~$2 Billion marketplace . Less attention from big players, significant opportunity to achieve leadership position . Clinical innovations and standards still forming . Early in adoption curve – competitive shakeout still occurring . Opportunity to play consolidator with economies of scale

Address: 2 Manhattanville Road, 3rd Floor, Purchase, NY 10577-2113 Telephone: 914-253-8000 CEO: Jay Higham Web Site: http://www.integramed.com/inmdweb/ State or other jurisdiction of incorporation or organization: DE Investor Contact: Jaffoni & Collins Incorporated, David Collins, Norberto Aja, inmd@jcir.com, 212-835-8500

MANAGEMENT

Jay Higham – President & CEO – Architect of diversification strategy, 13 years with INMD

Joe Travia – President, Fertility Centers Division – has led double digit same clinic Growth

Daniel Doman – President, Vein Clinics division – Former CFO promoted May, 2008

Pam Schumann – President, Consumer Services Division – has led and grown the segment to its current leadership position in the market

John Hlywak – EVP & CFO – 20+ years healthcare public market finance experience

Scott Soifer – SVP, Administration & Development – has led healthcare marketing & strategy activities for over 18 years

IPOdesktop (ID) SAFE HARBOR STATEMENT: Statements contained in this document, including those pertaining to estimates and related plans, potential mergers and acquisitions, estimates, growth, establishing new markets, expansion into new markets and related plans other than statements of historical fact, are forward-looking statements subject to a number of uncertainties that could cause actual results to differ materially from statements made. ID provides no assurance as to the subject company's plans or ability to effect any planned and/or proposed actions. ID has no first-hand knowledge of management and therefore cannot comment on its capabilities, intent, resources, nor experience and makes no attempt to do so. Statistical information, dollar amounts, and market size data was provided by the subject company or its agent and related sources believed by ID to be reliable, but ID provides no assurance, and none is given, as to the accuracy and completeness of this information.

DISCLAIMER: The information, opinions and analysis contained herein are based on sources believed to be reliable but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. Past performance is no guarantee of future results. ID has not been paid for preparation and posting of this report and other advertising services. Nevertheless, there may be a conflict of interest as to ID’s ability to remain objective in its communication regarding the subject company. Analysts, principals, associates and employees of ID do not own or trade equities under coverage. For detailed disclosure as required by Rule 17b of the Securities Act of 1933/1934 contact IPOdesktop, 11693 San Vicente Blvd., #350, Los Angeles, CA 90049. ID is not an investment advisor and this report is not investment advice. This information is neither a solicitation to buy nor an offer to sell securities but is an advertisement. Information contained herein contains forward-looking statements and is subject to significant risks and uncertainties, which will affect the results. The opinions contained herein reflect our current judgment and are subject to change without notice. We encourage our readers to invest carefully and read the investor information available at the web sites of the U.S. Securities and Exchange Commission (SEC) at http://www.sec.gov and the National Association of Securities Dealers (NASD) at http://www.nasd.com. The NASD has published information on how to invest carefully at its web site. Readers can review all public filings by companies at the SEC's EDGAR page.